

# Rudy Li Joins Wolfe Research

## Premier Research Firm Expands Biotech Coverage

**New York, NY** – February 5, 2026 – Wolfe Research, LLC is pleased to announce that Dr. Rudy Li has joined the firm as a Director and Senior Research Analyst. He is scheduled to launch coverage of Biotechnology stocks with a focus on the Central Nervous System (CNS) in the first quarter of 2026.

Rudy joins most recently from Chardan, where he served as a Director of Biotech Equity Research covering CNS-focused companies. Prior to Chardan, he spent over six years at Leerink Partners as a Vice President supporting coverage of 30+ biotech companies predominantly focused on CNS stocks. He holds a Ph.D. in Chemistry from Stony Brook University, a B.S. in Chemistry from Jilin University, and is a CFA charter holder.

Founder and Managing Partner Ed Wolfe stated, “Rudy has extensive expertise in the science and research of CNS therapeutics and his background in chemical biology and drug discovery informs his unique view on the sector. Rudy’s CNS-focused biotech coverage will complement our existing top ranked healthcare franchise, particularly our emerging therapeutics team that includes Alex Hammond, Andy Chen, and Kalpit Patel who bring strong focuses in the disciplines of immunology and immunization, rare diseases, genetic medicines, RNA/gene therapy, cardiometabolic diseases, and now CNS disorders. Our goal as a firm is to independently cover about 100 biotechnology stocks by the end of 2027—while retaining the top quality and unique insights that Wolfe Research has built its reputation on in all the sectors and stocks we choose to cover.”

Dr. Li commented: “I’m excited to build differentiated coverage of the fast-evolving CNS space across multiple emerging therapeutic areas. Wolfe’s independent approach and commitment to rigorous research makes it the perfect place to develop this franchise. I’m looking forward to collaborating with Alex, Andy, and Kalpit on the therapeutics team, and more broadly Wolfe’s accomplished Healthcare analysts including highly ranked analysts Mike Polark in Medical Devices, Doug Schenkel in Life Science & Tools, and Justin Lake in Healthcare Facilities & Managed Care.”

## About Wolfe

Since Wolfe Research, LLC’s founding in 2008, our mission has been to deliver best-in-class research and service—providing timely, rigorous, and unconflicted insights from the most differentiated, thoughtful and driven Analysts on the Street. Today, Wolfe is widely recognized as the premier, scaled independent equity research platform.

In 2025, Wolfe ranked #6 in the prestigious Extel All-America Research Poll, outperforming nearly every major firm aside from the largest global investment banks. Our realizable goal is to be each of our client’s most valued research counterparty.

Currently, Wolfe features 30+ Analyst teams covering all major GICS sectors, as well as portfolio strategy, economics, Washington policy, accounting, special situations, and technical analysis. Our award-winning QES (Quantitative, Economics & Strategy) team provides investible solutions, data feeds, advanced portfolio analytics, risk-management tools, and thoroughly back-tested alternative data.

In a marketplace increasingly saturated with massive amounts of often potentially clashing information and data, Wolfe, unconflicted by banking and other competing areas for research’s attention, is able to focus and deliver to its clients actionable, high-quality investment ideas grounded in rigorous fundamental research and supported—where appropriate—by clean data, analytics, and differentiated, tested market signals.

Our services are delivered through a research-focused, commission-based Sales team that actively partners with clients to help them extract, interpret, and apply Wolfe’s industry-leading intellectual capital.

Beyond research, Wolfe clients benefit from equity and derivatives trading and liquidity-provisioning capabilities through several key Prime Brokers. Our strategic alliance with Nomura and Instinet allows Wolfe to offer seamless high and low-touch global equity execution, as well as a top-ranked derivatives platform for options and swap trading. The Wolfe | Nomura Alliance also allows us to participate selectively in high-end capital-markets and advisory opportunities.



Wolfe Research and its affiliates currently operate across New York, London, Madrid, Sydney, Toronto, Boston, Mumbai, San Francisco, Los Angeles, Houston, Chicago, and Miami. We continue to actively recruit top talent. For more information, please visit [WolfeResearch.com](http://WolfeResearch.com)

**Business Inquiries**

Jon Stenzler  
Global Head of Institutional Sales  
[sales@WolfeResearch.com](mailto:sales@WolfeResearch.com)  
415-878-6415

**Media**

Media Relations  
[media@WolfeResearch.com](mailto:media@WolfeResearch.com)